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EVALUATION OF NEXT-GENERATION SEQUENCING AS A CLINICAL AND 
RESEARCH MODALITY IN THE DIAGNOSIS OF HEREDITARY BREAST 
CANCER 
 
KRISTEN ELIZABETH DOUGHERTY 
ABSTRACT 
 Next-Generation Sequencing has opened the doors to nearly limitless 
amounts of genomic data, but the clinical utility of this data is not yet clear. From 
examining at sequencing data of known familial cancer genes in hereditary 
cancer patients, the NCGENES study found a clear molecular diagnosis in about 
5% of patients and an uncertain molecular result in about 15% of patients. The 
remaining 80% of hereditary cancer patients received a negative result for the 
screening of known cancer genes. These latter patients were followed up by 
whole exome sequencing analysis, and the data was used to perform a research 
sweep to potentially identify mutation(s) in gene(s) that have yet to be clearly 
associated with their phenotype. 
 Hereditary breast cancer has a relatively well-established set of 
susceptibility genes, yet a large percentage of the molecular etiology is still 
unknown. There are many genes that are good candidates for breast cancer 
genes based on their protein’s function, but they may not actually contribute to 
breast cancer susceptibility. The ClinGen consortium is aiming to establish the 
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clinical validity of gene-disease associations so that clinicians and patients can 
better interpret and utilize sequencing results.  
Six breast cancer susceptibility genes were evaluated using the ClinGen 
clinical validity framework with the goal of both evaluating the genes already on 
hereditary breast cancer panels and evaluating genes not yet widely tested to 
determine if there is enough evidence to support their role in disease to warrant 
widespread testing. These genes have varying levels of evidence supporting 
their role in breast cancer susceptibility. The variants in each of the six genes 
were compared between a cancer patient cohort and a non-cancer patient cohort 
enrolled in the NCGENES whole exome sequencing study. One likely pathogenic 
variant and several variants of unknown significance were identified in various 
genes, and the burden of variants in cancer cases versus controls was 
evaluated, although the controls were not matched to the cancer cohort in any 
way. Research sweeps were performed for patients with VUSs to ensure that 
there were no other mutations in genes that would better fit the phenotype. 
 This thesis presents a method for evaluating gene-disease associations 
and for utilizing whole exome sequencing data to pinpoint a molecular diagnosis 
in hereditary breast cancer patients. Overall, it was found that the ClinGen 
method of evaluating clinical validity of gene-disease associations could be 
helpful when determining if variants are pathogenic or benign. A new gene, 
RINT1, was found to have enough evidence to be moderately associated with 
hereditary breast cancer and it was subsequently added to the diagnostic list so 
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that all cancer patients will now be screened for RINT1 variants. In addition, it 
was found that two of the genes currently on the diagnostic list, RAD51C and 
RAD51D, have “disputed” evidence with respect to breast cancer susceptibility. 
Interestingly, they have much more evidence for an association with ovarian 
cancer, so if variants are found in these genes, the patient’s phenotype should be 
considered when evaluating them. It was also shown that PALB2, an established 
breast cancer susceptibility gene, indeed is definitively associated with breast 
cancer, and the NCGENES cancer patients have more truncating variants than 
the controls, further validating the clinical validity assertion. Finally, an ovarian 
cancer patient with two interesting variants, one in SLX4 and one in GEN1, were 
evaluated. Studies showed that knocking out both of these genes’ pathways was 
highly destructive to the cell. A VUS was found in each of these genes, and it 
was hypothesized that perhaps these two variants together may be sufficient to 
contribute to this patient’s cancer susceptibility.  
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INTRODUCTION  
 Many types of cancer have been shown to be hereditary or familial. The 
most common hereditary cancers are colorectal, pancreatic, stomach, breast and 
ovarian cancers (Cancer Support Community, 2014). Hereditary cancer is often 
suspected when there are multiple close relatives that have all developed the 
same type of cancer. There are also cancer syndromes, such as Lynch 
Syndrome, that are rare, but that predispose to multiple types of early-onset 
cancer (American Cancer Society, 2014). Hereditary cancer is inherited via 
germline mutations in a set of genes that, when damaged, cause a variety of 
cellular abnormalities (National Cancer Institute, 2013). Overall, inherited 
mutations are estimated to be responsible for about 5-10% of all cancers 
(National Cancer Institute, 2013). 
 There are some genes that are associated with multiple cancers, while 
some seem to be associated with a specific type of cancer. These genes can 
have varying degrees of severity with respect to risk of developing cancer.  
In 2015 breast cancer will be responsible for about 40,000 deaths 
(American Cancer Society, 2015). Breast cancer incidence is on the rise in 
America. In the 1970s the lifetime risk for developing breast cancer for women 
was about 10%, while in 2009 the lifetime risk increased to 12.4% (National 
Cancer Institute, 2012). It is estimated that about 10% of breast cancer cases are 
hereditary and follow an autosomal dominant inheritance pattern, and an 
additional 15-20% are familial, meaning that there are multiple relatives affected, 
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but the inheritance is not perfectly autosomal dominant (Economopoulou, 2015).  
 There are several known breast cancer susceptibility genes. Some genes, 
like BRCA1 and BRCA2 for breast cancer, are highly penetrant, meaning that if 
there is a mutation that affects the protein function the individual may have up to 
an 87% chance of developing breast cancer (Barnes, 2012). There are also 
moderate and low penetrance genes for breast cancer, which increase an 
individual’s risk for breast cancer by a more modest percentage. For example, 
individuals with an inherited PALB2 mutation have a 33-58% chance of 
developing breast cancer by age 70 (Antoniou, 2014). 
Of the hereditary breast cancer cases, only about 30% are due to high 
penetrance BRCA1 or BRCA2 mutations (Siegel, 2013). Researchers have spent 
years trying to find genes to explain the remaining percentage of hereditary 
breast cancer. The most common approach to finding new breast cancer 
susceptibility genes is identifying good candidate genes based on the protein’s 
function in the cell. For example, many known breast cancer susceptibility genes 
play a role in resolving Holliday junctions and homologous recombination. This 
has led researchers to conduct case-control studies on other genes that have a 
similar cellular function or that interact with the already known genes to 
determine if they too play a role in breast cancer susceptibility. In some genes, 
such as BRCA2, PALB2, and RAD51C, individuals with homozygous or 
compound heterozygous mutations develop a more severe phenotype called 
Fanconi Anemia (D’Andrea, 2010). This disease predisposes to multiple different 
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types of very early-onset cancer as well as other phenotypic characteristics (Kee, 
2012). Many Fanconi Anemia genes are also breast cancer susceptibility genes 
when an individual has a monoallelic mutation (Levy-Lahad, 2010). 
Another approach to gene discovery is to utilize whole exome sequencing 
data. Whole exome sequencing (WES) is an efficient way to obtain sequence 
data for the majority of coding regions in the genome. A major area of research is 
focused on determining if there is significant clinical utility for WES and if WES 
should be ordered regularly as a test for people with suspected genetic disease. 
Traditionally physicians and labs used single gene tests to determine the cause 
of a genetic disease. The focus has now switched to phenotype-specific gene 
panels, such as the BROCA panel at the University of Washington for general 
cancer risk or BreastNext offered by Ambry Genetics for hereditary breast cancer 
(University of Washington Laboratory Medicine, 2015; Ambry Genetics, Aliso 
Viejo, CA). This is an inexpensive and efficient way to screen most or all of the 
genes known to be associated with breast cancer. The problem with gene panels 
lays in the fact that such a large percentage of hereditary breast cancer still has 
an unknown molecular etiology. It is this fact that drives the hypothesis that 
whole exome sequencing may be clinically useful for people with hereditary 
cancer. However, by utilizing whole exome sequencing or increasing the size of 
gene panels to include genes that are not as well studied, more variants of 
unknown significance (VUS) will be found and more patients will receive an 
uncertain result.  
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In this thesis, I evaluated the clinical validity of six candidate genes and 
analyzed the variants in these genes in a cohort of hereditary cancer patients 
and controls seen at the University of North Carolina – Chapel Hill. Using the 
patients’ WES data, I was able to identify potentially pathogenic variants in 
multiple patients that would not have been seen on a traditional gene panel for 





Clinical Validity Assertions   
The process used to evaluate clinical validity of gene-disease associations 
was developed by the Gene Curation Working Group of the Clinical Genome 
Resource (ClinGen) Consortium. The process involves an extensive literature 
review. Several different types of studies are curated from literature searches to 
form an assertion about the strength of the gene-disease pair, including reports 
of humans subjects with pathogenic variants in the gene that also have the 
phenotype. Pathogenicity of specific variants is assessed based on the 2015 
ACMG criteria for pathogenicity (Richards, 2015. Figure 1 summarizes the 
criteria for determining individual variant pathogenicity. 
 After curating papers, the information is assessed based on parameters 
agreed upon by the ClinGen consortium, and a clinical validity assertion is made. 
These rules have been tweaked based on recommendations from experts and 
curation of example genes. There are seven clinical validity classifications in the 
ClinGen scheme, ranging from “definitive” to “evidence against”. Figure 2 
describes the criteria for each clinical validity classification, and Figure 3 shows 
the assertion matrix used to determine a gene’s clinical validity (Clinical Genome 
Resource, 2014). A curator assigns a score of 0-5 for each of the categories in 
the matrix. The scores are then totaled and an assertion is made based on these 
parameters: 0-8 is “Limited,” 9-12 is “Moderate,” 13-16 is “Strong,” and 17-20 is 
“Definitive.” If there is convincing evidence refuting the gene-disease association, 
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the assertion is “Disputed” if the total score is greater than 8 and “Evidence 
Against” if the total score is less than 8. As an additional caveat, when 
considering the amount of time that a gene has been associated with disease, if 
there are 2 or fewer total studies identifying pathogenic variants in the gene, the 
highest score the gene can receive for time is a “1,” regardless of how long ago 
the papers were published. If there are more than two studies with pathogenic 
variants, then the score is based on how many years have passed since the first 
publication. Though the assertion matrix is very useful, it is meant only to be a 
guide and a summary of the information known about a gene-disease pair. 
Occasionally the assertion matrix may give a clinical validity classification that the 
curator does not agree with, especially in cases where there is refuting evidence. 
In this case the curator discusses the issues with a team of experts and together 
a determination about the gene’s clinical validity is made. The clinical validity 
assertions along with supporting evidence for those assertions will go into a 















• Benign:	  The	  minor	  allele	  frequency	  is	  too	  high	  for	  the	  particular	  disease	  or	  there	  is	  signi8icant	  observation	  of	  the	  variant	  in	  controls	  is	  strong	  evidence.	  • Pathogenic:	  The	  variant	  is	  not	  present	  in	  population	  databases	  or	  the	  prevalence	  of	  the	  variant	  is	  statistically	  increased	  in	  cases	  over	  controls.	  Population	  Data	  
• Benign:	  The	  variant	  is	  silent	  and	  there	  is	  no	  predicted	  amino	  acid	  change	  or	  if	  the	  variant	  occurs	  in	  a	  suspicious	  region	  of	  the	  gene.	  • Pathogenic:	  A	  novel	  missense	  variant	  in	  an	  amino	  acid	  residue	  that	  a	  different,	  pathogenic	  missense	  variant	  has	  previously	  been	  reported,	  a	  protein	  length	  changing	  variant,	  or	  a	  missense	  variant	  that	  causes	  the	  same	  amino	  acid	  change	  as	  a	  previously	  reported	  pathogenic	  variant.	  Sequence	  Analysis	  
• Benign:	  Prediciton	  algorithms	  anticipate	  that	  the	  variant	  will	  not	  be	  damaging.	  • Pathogenic:	  Multiple	  prediction	  algorithms	  anticipate	  that	  the	  variant	  will	  be	  damaging	  to	  the	  gene	  product	  or	  a	  variant	  predicted	  to	  be	  truncating	  in	  a	  gene	  where	  loss-­‐of-­‐function	  is	  a	  known	  mechanism	  for	  disease.	  in	  silico	  Prediction	  
• Benign:	  Well-­‐established	  functional	  studies	  show	  that	  the	  variant	  has	  no	  detrimental	  or	  deleterious	  effect	  on	  the	  protein.	  • Pathogenic:	  Well-­‐established	  functional	  studies	  show	  that	  the	  variant	  has	  a	  detrimental	  or	  deleterious	  effect	  on	  the	  protein,	  or	  a	  missense	  variant	  in	  a	  gene	  that	  does	  not	  normally	  have	  a	  lot	  of	  benign	  variatioin	  or	  in	  a	  functional	  domain	  that	  does	  not	  have	  cited	  benign	  variation.	  Functional	  Data	  
• Benign:	  The	  variant	  does	  not	  segregate	  with	  the	  disease.	  The	  variant	  is	  observed	  in	  trans	  with	  a	  dominant	  or	  observed	  in	  cis	  with	  a	  pathogenic	  variant.	  • Pathogenic:	  The	  variant	  co-­‐segregates	  with	  the	  disease	  in	  multiple	  family	  members.	  The	  variant	  is	  detected	  in	  trans	  with	  a	  pathogenic	  variant	  (recessive	  disorders).	  The	  variant	  is	  de	  novo	  with	  con8irmed	  maternity	  and	  paternity.	  
Family	  Inheritance	  Pattern	  
• Benign:	  The	  variant	  is	  found	  in	  a	  case	  with	  an	  alternate	  genetic	  cause.	  • Pathogenic:	  The	  patient's	  phenotype	  is	  hightly	  speci8ic	  for	  the	  gene	  containing	  the	  varaint.	  Other	  Data	  
Criteria used to evaluate the pathogenicity of reported variants. This 
was adapted from the 2015 ACMG Guidelines for variant curation 
(Richards, 2015). 
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Figure 2. ClinGen Clinical Validity Classifications 
Evidence Level Evidence Description and Selected Examples 
DEFINITIVE 
evidence for a 
causal role in 
disease 
The role of this gene in this particular disease has been repeatedly 
demonstrated (in ≥ 20 unrelated probands) in both the research and 
clinical diagnostic settings, and has been upheld over time (at least 3 
years).  No valid evidence has emerged that contradicts the role of the 
gene in the specified disease. 
 
STRONG 
evidence for a 
causal role in 
disease 
There is strong evidence by at least two independent studies to 
support a causal role for this gene in this disease, such as: 
• Strong statistical evidence demonstrating an excess of 
pathogenic variants in affected individuals as compared to 
appropriately matched controls 
• Multiple pathogenic variants within the gene in unrelated 
probands with several different types of supporting 
experimental data.  The number and type of evidence might 
vary (e.g. fewer variants with stronger supporting data, or more 
variants with less supporting data) 
MODERATE 
evidence for a 
causal role in 
disease 
There is moderate evidence to support a causal role for this gene in 
this disease, such as: 
• At least 3 unrelated probands with pathogenic variants within 
the gene with some supporting experimental data.   
The role of this gene in this particular disease may not have been 
independently reported, but no valid evidence has emerged that 
contradicts the role of the gene in the noted disease.  
LIMITED 
evidence for a 
causal role in 
disease 
There is limited evidence to support a causal role for this gene in this 
disease, such as: 
• Fewer than 3 observations of a pathogenic variant in the gene  
• Multiple variants reported in unrelated probands but without 
sufficient evidence for pathogenicity per 2014 ACMG criteria 
NO REPORTED 
EVIDENCE for a 
causal role in 
disease 
No evidence reported for a causal role in disease.  These genes might 
be “candidate” genes based on animal models or implication in 
pathways involved in human diseases, but the genes themselves have 
not been reported as having pathogenic variants in humans. 
DISPUTED 
evidence for a 
causal role in 
disease 
Valid evidence of approximate equivalent weight exists both supporting 
and refuting a role for this gene in this disease. 
EVIDENCE 
AGAINST a 
causal role in 
disease 
Evidence refuting the role of the gene in the specified disease has 





Whole Exome Sequencing Library Preparation   
Whole blood was donated by NCGENES participants and DNA was 
extracted by the Biospecimen Processing Facility at UNC-Chapel Hill. One 
aliquot of DNA was sent to the Berg lab, and the other sent to the CLIA certified 
UNC Hospitals Molecular Diagnostic lab at UNC-Chapel Hill. DNA was sheared 
on a focused-ultrasonicator (Covaris, Woburn, MA), and subsequently entered 
into the library preparation process. Whole exome sequencing library preparation 
was performed using the Agilent SureSelectXT Human All Exon enrichment kit 
(Agilent Technologies, Santa Clara, CA). Some library preparation was done by 
hand, and some was done on the Agilent Bravo Automated Liquid Handling 
Figure 3. Clinical Validity Assertion Matrix 
 
 
The clinical validity assertion matrix is used to determine the level of association 
between a gene and a disease. After curating the published literature for a specific 
gene, the information can be summarized in this matrix and an assertion is made. 
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Platform (Agilent Technologies, Santa Clara, CA). The protocol given by Agilent 
for SureSelectXT was followed with a starting input of about 3µg of DNA. After 
library preparation pools of four prepared libraries with different index tags were 
submitted to the UNC High Throughput Sequencing Facility for sequencing, and 
the results were returned to the molecular analysts in the Berg Lab. 
Study Subjects   
 Both the cancer cases and the controls used in this analysis were patients 
enrolled in the NCGENES study from 2012 to 2014. All subjects were seen in the 
UNC Genetics Clinic. The controls were patients with suspected genetic 
disorders other than hereditary cancer, and they were in no way age or race 
matched to the cancer cohort. This is important because the control cohort is not 
made of up true “controls.” The control cohort includes a significant number of 
pediatric patients, and we would not have expected them to develop cancer yet, 
even if they had a pathogenic variant in a hereditary cancer gene (See RINT1 
chapter). 
The cohort includes 102 cancer patients and 303 controls. The cancer 
cohort is 88% white, 5% African-American, 5% other or not reported, 2% Native 
American, and 1% Asian. The control cohort is 78.2% white, 17% African-
American, 2% other or not reported, 1.3% Asian, 1.7% Native American, and 
0.3% Pacific Islander. Thus, they do not make a perfect control cohort, which is 
one limitation of this study.  
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Variant Analysis and Research Sweeps   
Though variants were called in the whole exome, only variants in specific 
genes were initially analyzed for each patient. These genes were on a 
predetermined diagnostic list tailored to the individual patient’s phenotype. Based 
on the clinical validity of gene-disease associations, genes are added and 
removed from a given diagnostic list.  
 Molecular analysts researched the variants for each patient and 
designated them “Known Benign” (KB), “Likely Benign” (LB), “Variant of 
Uncertain Significance” (VUS), “Likely Pathogenic” (LP), or “Known Pathogenic” 
(KP) according to the ACMG guidelines (Richards, 2015). A known pathogenic 
variant must have been previously reported in a patient and shown to be 
pathogenic for the particular disease. Along the same lines, a known benign 
variant must have been previously reported to not have an association with the 
disease. The other 3 categories (LP, LB, and VUS) rely on the molecular analyst 
to investigate the potential pathogenicity of the particular variant based on 
several parameters. 
 When an analysis of the variants in genes on the diagnostic list does not 
turn up a pathogenic variant, a research sweep may be conducted. This involves 
looking at candidate variants from the rest of the patient’s whole exome 
sequencing data to identify a variant in a gene that may potentially fit the 
phenotype, but is not currently known to be implicated in hereditary cancer 
predisposition and thus not included on the diagnostic list. These genes could be 
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candidate genes that do not yet have enough evidence to be included on the list, 
or novel genes that have no evidence implicating an association with cancer, but 
fit the phenotype due to gene or protein product function. A research sweep 
query will return thousands of variants. The variants are filtered based on 
population frequency, type and location of variant, in silico prediction algorithms. 
CADD PHRED scores were part of the CANVAS database output and are a 
numerical score predicting how damaging a variant may be to a protein (Bizon, 
2014; Kircher, 2014). In addition to CADD PHRED scores, I used two outside 
tools: PolyPhen-2 and SIFT, which work in a similar way (Adzhubei, 2010; 
Kumar, 2009). These algorithms are not always predictive of pathogenicity, but 
they can provide supporting in silico evidence. Truncating variants and the 
missense variants with the highest CADD PHRED scores are evaluated. When 
interesting variants are found in novel genes, one must search the literature to 
determine the function of the protein to conclude if it logically fits the phenotype 
you are looking at. If so, the variant may be evaluated further using several 
methods. 
 There are six main categories of data to consider when evaluating the 
pathogenicity of a given variant (Figure 2). When considering population data 
minor allele frequency data reported in ExAC is used to ensure that the variant is 
not more common than the disease (Exome Aggregation Consortium, 
Cambridge, MA). ExAC shows overall frequency data, but also breaks it down 
into frequencies in specific subpopulations. The UCSC Genome Browser is the 
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most common tool used for sequence analysis (Kent, 2002). One can search for 
the position of the variant in the Genome Browser and then analyze the 
surrounding sequence to see if the variant could possibly be an artifact or 
insignificant. For example, if the variant is in a highly repetitive region of the 
genome there is a good chance that there was a sequencing error. In addition, if 
a variant is truncating but at the very end of the protein, then it likely does not 
completely diminish the protein’s function. A splice-site variant must also be 
closely analyzed to confirm that the variant will actually affect splicing of the 
exon. For example, if there was a deletion of a T in the intron, but the next base 
is also a T, the splice site would not actually be affected and the variant would 
likely not be pathogenic. Functional data can be gathered from a careful review 
of published literature about a specific variant. Data about other variants in the 
same region of the gene could also provide some supporting evidence if the 
variant in question is novel. Inheritance patters can be ascertained from family 
segregation studies in published literature. This data could range from supporting 
evidence to strong evidence for pathogenicity, depending on the number of 
family members that can be tested and how well the variant segregates with 
disease. This can be challenging with adult onset disease, because some of the 
family members may possess the variant but not yet show the phenotype. Taken 
together, these forms of data analysis can provide evidence in support of the 
variant being pathogenic, benign, or the evidence could be conflicting. 
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RESULTS 
 Below are the results of the analysis of six breast cancer susceptibility 
genes separated. Each section includes a review of the literature used in making 
a clinical validity assertion, a review of the variants seen in NCGENES cancer 
patients and controls, and a case-report if an interesting variant was discovered. 
RINT1   
RAD50-Interacting Protein 1 (RINT1) was cloned in 2001 and found to be 
associated with the well-known RAD50 protein (Xiao, 2001). Immunoprecipitation 
experiments during different phases of the cell cycle showed that RINT1 
interacted with RAD50 only during late S phase and the G2/M checkpoint (Xiao, 
2001). This, along with the fact that RAD50 is involved in DNA double-stranded 
break repair and cell cycle checkpoint activation, led to the hypothesis that 
RINT1 may play a role in cell cycle regulation after DNA damage (Xiao, 2001). 
Since many breast cancer susceptibility genes are known to play a role in 
double-strand break repair, RINT1 became a suspect in the hunt for genes 
associated with hereditary breast cancer.  
Lin et al then showed that depletion of RINT1 with siRNA caused cell 
cycle abnormalities such as prolonged M phase, failure of the radiation induced 
G2/M checkpoint, and mitotic cell death in HeLa cells (Lin, 2007). Chromosomal 
missegregation and centrosome amplification also followed RINT1 depletion (Lin, 
2007). In a mouse model, homozygous deletion of RINT1 was embryonic lethal, 
and heterozygous RINT1 mice were prone to multiple tumors with an 81% tumor 
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incidence over their lifespan, a figure that is shockingly close to the lifetime risk of 
a BRCA1 mutation in humans (Lin, 2007; Barnes, 2012). The 2007 study by Lin’s 
group identified RINT1 as a tumor suppressor gene and, therefore, it became a 
good candidate gene for hereditary cancer.  	   These and other functional studies led researchers to believe that RINT1 
may play a role in familial breast cancer susceptibility. There have been no 
studies contradicting the claims of the functional studies or the case-control 
study.  
The first and only clinical report to date implicating RINT1 in familial 
cancer came in 2014 from Park et al. The group identified 3 RINT1 variants in a 
group of 89 women from 47 families with a strong history of breast cancer (Park, 
2014). The most interesting finding was a nonsense variant (c.343C>T) that 
apparently segregates with breast cancer in one family (Park, 2014). A total of 
four women in the family have breast cancer and all four have the nonsense 
variant (Park, 2014). Two female family members have the variant and have not 
yet been diagnosed with breast cancer, although they are rather young so they 
still have the potential to develop cancer (Park, 2014). In addition to increased 
breast cancer risk, RINT1 variants show a statistically significant increased risk 
for all non-breast cancers, but particularly for digestive tract and female genital 
cancers (Park, 2014). Because of this, Park et al hypothesized that RINT1 is not 
only a breast cancer susceptibility gene, but a gene involved in the entire Lynch 
Syndrome spectrum of cancers (Park 2014). 
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 The combination of the functional and case-control studies provided 
sufficient evidence for a “moderate” association of RINT1 with familial breast 
cancer (Figure 4C). The moderate clinical validity of RINT1 led it to be added to 
the cancer diagnostic list. All future NCGENES cancer patients will now be 
screened for RINT1 along with the other genes on the list. 
 The Park et al paper inspired a research sweep of our NCGENES WES 
data to determine if any of our cancer patients may be harboring a potentially 
pathogenic RINT1 variant (data in Figure 4B). It is notable that the cancer 
patient population appears to have more rare missense variants than the control 
population. The control population has one rare truncating variant, while the 
cancer cohort does not. However, the patient with the truncating RINT1 variant is 
a young child with an unknown family cancer history. Therefore, we cannot 
exclude the possibility that the patient will develop cancer in her adult life that 
may be attributable to this variant.  
   The distribution of rare RINT1 variants in NCGENES cancer patients can 
be seen in Figure 4A. NCG_00108 had a missense variant in the RAD50 binding 
domain (Asn740Ile). This variant is not reported in ExAC, suggesting that it is 
very rare. The replacement of asparagine with isoleucine is a significant amino 
acid change and could alter the function of a protein in the critical RAD50 binding 
domain. The in silico prediction algorithms had conflicting results, but two out of 
three predicted the variant to be damaging. Overall, there was not sufficient 
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evidence to classify this variant as pathogenic, so it was interpreted as being a 
VUS.  
NCG_00108 had gone through the cancer diagnostic list screen and 
received a negative result. The patient was diagnosed with breast cancer at age 
54 and has a strong history of breast cancer on her maternal side. Her mother 
was diagnosed with breast cancer at age 23 and she has two aunts on her 
maternal side diagnosed with breast cancer: one at age 45 and one in her 60s. 
Upon identification of this variant, a research sweep was performed on 
NCG_00108. No other variants were a better fit for this patient’s phenotype, 
suggesting that this variant may indeed be playing a role in the participant’s 
personal and family history of cancer. Further studies including family 
segregation analysis will be required to better understand the role of this variant. 
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A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) RINT1 
variants in NCGENES cancer patients (Park, 2014). Note Pro759Leu was seen in two 
patients. Dark gray denotes a VUS, and light gray denotes a likely benign variant. Note 
that Trp787* was found in a control. B. Clinical validity matrix for RINT1 used to make the 
assertion of “moderate” for this gene. C. RINT1 variant count table showing number of 
variants per patient using different filters on NCGENES cancer cases and controls. 
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SLX4 and GEN1   
SLX4 structure specific endonuclease subunit (SLX4) was discovered in 
2009 by Fekairi et al, who were searching for sequences similar to fungal Slx4 
and Drosophila Mus312 (Fekairi, 2009). The group also found that SLX4 is 
required for interstrand crosslink repair, and it interacts with two endonucleases: 
XPF and MUS81 (Fekairi, 2009). To further support the hypothesis for the role of 
SLX4, Muñoz et al found that depletion of SLX4 causes a decrease in double 
stranded break-induced homologous recombination and hypersensitivity to toxins 
that cause double stranded breaks (Muñoz, 2009). Studies showed that the 
SLX1-SLX4 complex promotes symmetrical cleavage of Holliday Junctions, 
establishing the complex as an HJ resolvase (Svendsen, 2009). SLX4 is 
associated with many protein complexes that have similar functions in DNA 
repair. In addition to these studies, a SLX4 null mouse model showed a 
phenotype similar to FA (Crossan, 2011). Because genes known to be 
associated with FA are often also breast cancer susceptibility genes, there was 
further speculation that germline SLX4 variants could predispose families to 
breast cancer. 
 There have been several attempts to find deleterious mutations in SLX4 
(Bakker, 2013; Catucci, 2012; de Garibay, 2013; Fernández-Rodríguez, 2012; 
Kurian, 2014; Landwehr, 2011; Shah, 2013). Although many of these efforts did 
not identify convincing pathogenic variants, four groups have proposed that 
truncating variants in SLX4 may be implicated in hereditary breast cancer 
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susceptibility. Bakker et al were the first to identify a truncating SLX4 mutation in 
a breast cancer patient (Bakker, 2013). In their study they screened SLX4 in 729 
BRCA1/2 negative familial breast cancer patients (Bakker, 2013). The group 
identified 102 variants, most of which were benign, though they did identify one 
splice-site variant in a single proband (c.2013+2T>A) (Bakker, 2013). Through 
PCR they found that this variant caused skipping of exon 8 and resulted in a 
truncated protein (Bakker, 2013). Limited segregation analysis was performed, 
and the only two people in the family tested for the variant were both carriers 
(Bakker, 2013). One was the proband that was affected with breast cancer and 
the other was her daughter who, at the time of publishing, was not affected with 
breast cancer (Bakker, 2013). 	  
 In another study, 465 hereditary breast cancer patients were sequenced 
for SLX4 variants, and one truncating mutation was identified (de Garibay, 2013). 
The mutation p.Glu1517* codes for a protein lacking the C-terminal 318 amino 
acids, which includes the SLX1 binding domain (de Garibay, 2013). The proband 
had four other relatives diagnosed with breast cancer before age 50, but none of 
the samples were available for segregation analysis (de Garibay, 2013). The 
mutation was not detected in 480 controls (de Garibay, 2013). 
 Shah et al performed a SLX4 screen on 738 BRCA1/BRCA2 mutation 
negative breast cancer patients and identified a nonsense variant (p.Trp823X) 
(Shah, 2013). The patient was diagnosed with breast cancer in her 60s and her 
mother and grandmother were both diagnosed with breast cancer in their 60s 
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and 30s, respectively (Shah, 2013).  Using a human SLX4 null cell line, Shah et 
al performed cell sensitivity assays with MMC, a topoisomerase inhibitor and a 
PARP inhibitor to see if cDNA with the variant knocked in could remove this cell 
line’s sensitivity to these drugs (Shah, 2013). The Trp823X variant was not able 
to rescue resistance to the PARP inhibitor and the topoisomerase inhibitor and 
only partially rescued MMC resistance, demonstrating that this variant produces 
a protein with little or no function (Shah, 2013). 
Finally, in a screen of 42 potential breast cancer susceptibility genes 
Kurian et al found a frameshifting insertion in SLX4 in 2 probands (Kurian, 2014). 
The first proband was diagnosed with breast cancer at age 61 and has 3 family 
members who were diagnosed with breast cancer in their 40s (Kurian, 2014). 
The second proband has no personal cancer history, but has a significant history 
of breast cancer in her family, with 3 family members being diagnosed with 
breast cancer before age 50 (Kurian, 2014). Kurian et al called this novel variant 
“potentially actionable,” and they recommended that the patients consider more 
intensive breast examinations due to the potential increased risk for breast 
cancer that this variant confers (Kurian, 2014).  
To summarize the data for SLX4, out of 2,036 familial breast cancer cases 
screened, 5 truncating variants were found. Taking this data, we can estimate 
that about 0.25% of hereditary breast cancer cases are caused by truncating 
mutations in SLX4. It remains unclear whether missense mutations in SLX4 
could contribute to cancer susceptibility. If certain missense mutations do 
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contribute, then the percentage of cases would increase slightly. However, in 
vivo and in vitro functional studies must be done before it can be assumed that 
missense variants are pathogenic. SLX4 was given a clinical validity 
classification of “strong” (Figure 5C). 
GEN1 Holliday junction 5’ flap endonuclease (GEN1) was discovered in 
2008 by Ip et al while aiming to identify Holliday junction resolvases in yeast and 
their orthologues in humans (Ip, 2008). Prokaryotes have their own version of a 
Holliday junction resolvase called RuvC (West, 1997). After the discovery of 
RuvC, it took over 10 more years to identify the human functional counterpart. 
GEN1 was identified via mass spectrometry after extensive fractionation of 
human cells (Ip, 2008). They also showed that recombinant GEN1 cleaves and 
resolves Holliday junctions symmetrically (Ip, 2008). Because proteins 
associated with Holliday junctions have been previously shown to be breast 
cancer susceptibility genes, GEN1 became a new suspect in the hunt for genes 
that contribute to heritable breast cancer. 
 GEN1 was also discovered to be a centrosome-associated protein, and 
GEN1 depletion leads to an excess of centrosomes, causing multipolar mitotic 
spindles and chromosomal missegregation (Gao, 2012). In a yeast mus81 
mutant that lacks a GEN1 homolog, introduction of normal human GEN1 
alleviates the meiotic lethality that results from chromosome missegregation 
(Lorenz, 2010). GEN1 depletion also led to increased multi-nucleation and 
apoptosis (Gao, 2012).  
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 Because there were reports of somatic truncating mutations in breast 
cancer tumors and cell lines, Sun et al sought to investigate the role of GEN1 in 
breast tissue in mice (Sun, 2014). Via mRNA and protein expression profiling, 
GEN1 protein was found to increase during initial mammary gland proliferation 
and peak during lactation in mammary epithelial cells, implying that it plays a role 
in normal mammary development and physiological function (Sun, 2014). Sun et 
al also confirmed centrosome localization of GEN1 in mouse mammary epithelial 
cells as well as verified GEN1’s role in DNA damage response in human 
mammary epithelial cells (Sun, 2014). When human mammary epithelial cells 
were treated with a drug that induces DNA single and double stranded breaks 
and a drug that halts DNA replication and causes double stranded breaks, GEN1 
protein levels were elevated (Sun, 2014). 
For several years, the only truncating GEN1 mutations found were 
somatic mutations in breast tumors (Forbes, 2008; Wood, 2007). In 2010 
Turnbull et al became the first group to analyze the full GEN1 gene in 176 
BRCA1/2 negative familial breast cancer patients and 159 controls (Turnbull, 
2010). They also genotyped six SNPs to tag 30 common variants in GEN1 to 
perform an association analysis in 3,750 breast cancer cases and 4,907 controls 
(Turnbull, 2010). A truncating variant was identified at the end of the gene 
(c.2515_2519delAAGTT), however, it was present in both cases and controls at 
the same frequency and a control individual was found to be homozygous for the 
variant (Turnbull, 2010). Based on this data, Turnbull et al concluded that the 
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final 69 amino acids of the GEN1 protein are nonessential to the protein’s 
function (Turnbull, 2010). In addition, none of the 30 common variants showed a 
particular association with breast cancer, which led Turnbull et al to hypothesize 
that GEN1 does not act as high or intermediate penetrance breast cancer 
susceptibility gene nor do common variants act as low penetrance contributing 
alleles (Turnbull, 2010). 
 In 2012, Kulinga et al conducted a different type of study looking for 
recessively acting breast cancer susceptibility alleles (Kuligina, 2013). They 
genotyped the same variant previously reported (c.2515_2519delAAGTT) in 360 
patients, 280 of which had no maternal history of breast cancer but multiple 
primary malignancies, and 1305 controls (Kuligina, 2013).  The analysis revealed 
that patients with bilateral breast cancer have a significantly higher incidence of 
homozygosity for this variant than controls (Kuligina, 2013). All instances of 
homozygous c.2515_2519delAAGTT were in patients whose mothers did not 
have breast cancer (Kuligina, 2013). This may indicate that GEN1 acts as a 
recessive breast cancer susceptibility allele rather than an autosomal dominant 
allele. Notably, this difference did not hold true in unilateral breast cancer 
patients (Kuligina, 2013). To date c.2515_2519delAAGTT remains the only 
truncating GEN1 variant identified in humans. Based on the evidence in the 
literature, GEN1 was given a clinical validity classification of “disputed” (Figure 
6C). 
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 SLX4 and GEN1-MUS81 are two very similar, but genetically distinct 
pathways for resolving Holliday junctions, and have largely overlapping functions 
as HJ resolvases in response to DNA damage (Wyatt, 2013). Defects in either or 
both of these pathways result in catastrophic chromosomal abnormalities (Wyatt, 
2013). BTR is different pathway for Holliday junction processing and is likely what 
provides the main mechanism for HJ resolution during S phase of the cell cycle, 
with the other two pathways playing a role during G2/M phase (Sarbajna, 2014). 
Bloom’s syndrome patients have defective BTR pathways, so Wechsler et al 
hypothesized that the SLX4, GEN1 and MUS81 pathways may be able to at least 
partially substitute for the loss of the BTR pathway in these patients (Wechsler, 
2011). Without inflicting exogenous DNA damage, they observed loss of cell 
viability when depleting any two of the three pathways at the same time via 
siRNA targeting (Wechsler, 2011). Depletion of both GEN1 and SLX4 had the 
greatest impact on cell viability and also had the most severe chromosomal 
abnormalities such as missegregation and segmentation (Wechsler, 2011).  
Sarbajna et al showed that even in BLM proficient cells depletion of GEN1 
and SLX4 leads to genome instability throughout the entire cell cycle and 
delayed S phase progression (Sarbajna, 2014). They found that these defects, 
though, only occurred with co-depletion of GEN1 and SLX4, illustrating the 
functional redundancies of the two (Sarbajna, 2014). They also found that 
chromosome segmentation occurred upon codepletion of GEN1 and SLX4, 
similar to the phenotype observed in BLM and SLX4 deficient cells that Wechsler 
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et al tested (Sarbajna, 2014). A final finding was significant multinucleation in 
GEN1 and SLX4 codepleted cells, driving home the fact that these cells have 
significant impairments that are passed on to their daughter cells (Sarbajna, 
2014). 
 SLX4 is on the NCGENES cancer diagnostic list, and therefore the rare 
variants were all examined and signed out by a trained molecular analyst. SLX4 
seems to have a heavy mutational burden, as demonstrated by Figure 5A. 
NCGENES patients have a particular cluster of variants in the BTB domain, 
which is a protein-protein interaction domain. There are several VUS’s, but no 
pathogenic variants found in SLX4 in our cohort. This is likely due to (1) the lack 
of truncating variants found, and (2) a lack of confidence in the pathogenicity of 
missense variants due to the relatively few number of SLX4 variants published 
and functionally found to be pathogenic. Considering that SLX4 may only 
account for 0.25% of hereditary breast cancer cases, we would not necessarily 
expect to find any true positive SLX4 mutations in 102 cases. 
 It is also noteworthy that the cancer patients and the controls have the 
same number of variants per person in SLX4, but that cancer patients seem to 
have a higher burden of rare variants (Figure 5B). Interestingly, the only 
truncating variant found in SLX4 belonged to a control, NCG_00614. The variant 
is a frameshifting deletion early on in the protein at amino acid 207, and would 
therefore seem likely pathogenic. It is unclear if the deletion would cause 
skipping of one exon or protein truncation. Because the variant is not in a 
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functional domain, if the protein is not truncated then it is not necessarily 
surprising that the variant is not pathogenic. This patient is a 54-year-old male 
with Hemophilia and Charcot-Marie-Tooth disease. The family has no history of 
cancer, so it is unlikely that the SLX4 variant is a highly penetrant cancer allele. 
In addition, because the individual is male, he would not be expected to have 
developed breast cancer. Even families with highly penetrant BRCA1 or BRCA2 
mutations do not see many cases of male breast cancer because it is such an 
uncommon cancer to develop in men. 
 Because GEN1 is not on the diagnostic list, none of the variants had 
previously been annotated by molecular analysts. All of the rare variants in 
cancer patients were analyzed which can be seen in Figure 6A. Two were 
interpreted as being likely benign because they were either not in a functional 
domain or they were in a part of the protein known to be nonessential. Two were 
identified as VUSs. The first is Arg302His in NCG_00665. Though arginine to 
histidine is not a major amino acid change, the variant is located in the highly 
conserved H3TH domain. The H3TH domain is part of the PIN domain in GEN1, 
which is involved in nucleotide binding (NCBI, Bethesda, MD). The second VUS, 
in NCG_00097, is discussed in detail below. 
 NCG_00097 is a cancer patient run on the diagnostic list and found by our 
molecular analysts to have a VUS in SLX4 (p.Asn1834Ser, Figure 5A). The 
patient was diagnosed with ovarian cancer at age 35, and she has 2 maternal 
great aunts who were diagnosed with cancer in their 60s; one had breast cancer 
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and the other had ovarian cancer. Upon analyzing data from a research sweep of 
NCG_00097, I discovered a GEN1 variant that was also interpreted as a VUS 
(p.Ser189Asn, Figure 6A). The variant is in just over 1% of the population and is 
located in the PIN domain, which is involved in DNA binding and a very 
conserved region, though in silico prediction algorithms predict it to be benign or 
tolerated. There is significant functional data to suggest that damaging both of 
these HJ resolvase pathways could be damaging to the cell (Sarbajna, 2014; 
Wechsler, 2011; Wyatt, 2013). Taken together, the SLX4 and GEN1 variants 
may cause a sufficient loss of HJ resolvase activity to predispose NCG_00097 to 
cancer.  
 Overall, NCG_00097’s family history is not highly suggestive of an 
autosomal dominant hereditary cancer syndrome. This somewhat supports the 
hypothesis that this patient’s cancer may be related to an increased burden of 
damaging variants in both SLX4 and GEN1 that diminish HJ resolvase function. 
Her other family members may only have one of the variants while she has 
inherited both, which would explain why most of them have not developed 
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A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) SLX4 
variants in NCGENES cancer patients. Dark gray denotes a VUS and light gray denotes a 
likely benign variant (Kim, 2011). Note that three of the variants were found in two people 
each. B. Clinical validity matrix for SLX4 used to make the assertion of “strong” for this 
gene. C. SLX4 variant count table showing number of variants per patient using different 
filters on NCGENES cancer cases and controls. 
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 SUM TOTAL 9 Assertion: Disputed  
A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) GEN1 
variants in NCGENEs cancer patients. Dark gray signifies a VUS and light gray signifies a 
likely benign variant (Ip, 2008; Turnbull, 2010). Note that the Ser509Trp variant was found 
in two patients and the Ser189Asn variant was found in three patients. B. Clinical validity 
matrix for GEN1 used to make the assertion of “disputed” for this gene. C. GEN1 variant 
count table showing number of variants per patient using different filters on NCGENES 
cancer cases and controls. 
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PALB2    
Partner and Localizer of BRCA2 (PALB2) was discovered and cloned in 
2006 by Xia et al, who used mass spectrometry to identify proteins that 
precipitated with BRCA2 (Xia, 2006). Because it has such a strong interaction 
with BRCA2 there was a solid suspicion for a role in hereditary breast cancer 
(Xia, 2006). Xia et al found that PALB2 enabled BRCA2’s recombinational repair 
and checkpoint functions, which ensures that it can perform it’s tumor suppressor 
function (Xia, 2006). In a siRNA knockdown experiment, they found that HeLa 
cells with depleted PALB2 were sensitive to MMC, which is a hallmark of Fanconi 
Anemia (FA) (Xia, 2006). 
 Homozygous BRCA2 mutations cause FA type D. When Xia et al came 
across a patient with a new subtype of FA, they suspected that a PALB2 
mutation was the culprit (Xia, 2007). They found that they could not detect full 
length PALB2 in the cells of the patient, and when they ran further experiments 
they found that BRCA2 was mislocalized and RAD51 foci formation, usually 
induced by MMC, was impaired (Xia, 2007). Sequencing of genomic DNA and 
cDNA showed a maternally inherited nonsense mutation in exon 4 of PALB2 and 
a paternally inherited exon 4 deletion, thus making the patient a compound 
heterozygote (Xia, 2007). Simultaneously, Reid et al discovered biallelic PALB2 
mutations in 7 FA and early childhood cancer families (Reid, 2007). 
 Xia et al noted that several of the FA proband’s family members 
developed tumors (Xia, 2007). Because PALB2 is critical for the function of 
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BRCA2 and because biallelic mutations have a similar phenotype to biallelic 
BRCA2 mutations, it was plausible that monoallelic mutations could predispose 
to adult cancer (Reid, 2007). Rahman et al was the first to describe such 
mutations in familial breast cancer (Rahman, 2007). They found 10 truncating 
PALB2 mutations in familial breast cancer cases and none in controls, showing 
that truncating PALB2 mutations confer a 2.3 fold increased risk of getting breast 
cancer (Rahman, 2007). After these studies, PALB2 screening studies began to 
be performed in several populations around the world. Studies were performed in 
Finnish, Canadian, Australian, and Italian probands, all with similar results: 
PALB2 is undoubtedly a familial breast cancer susceptibility gene (Catucci, 2014; 
Erkko, 2007; Foulkes, 2007; Teo, 2013; Tischkowitz, 2007). PALB2 has been 
established as a “definitive” breast cancer susceptibility gene, and is on the 
NCGENES breast cancer diagnostic list as well as on the expanded hereditary 
breast cancer panels that are offered by diagnostic labs (Figure 7C).  
 In NCGENES patients there are more rare missense and rare truncating 
PALB2 variants in cancer patients than there are in controls (Figure 7B). There 
are 0.045 rare PALB2 variants per patient in cancer cases compared to 0.031 
per patients in controls. There are also 0.009 truncating PALB2 variants per 
patient in cancer cases and 0.003 per controls. This supports the hypothesis that 
PALB2 is a cancer susceptibility gene. 
 NCG_00139 is a woman diagnosed with breast cancer at age 40. She 
was found by molecular analysts to have a nonsense PALB2 variant at amino 
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acid 414 during the routine NCGENES case study (Figure 7A). This variant is 
predicted to truncate the protein in the middle of the nucleosome binding domain 
and the protein is, therefore, expected to lack the WD40/BRCA2 binding domain 
or to undergo nonsense mediated decay. In either case, the protein would not 
function properly. Xia et al reported a nonsense variant in the same area of the 
protein in their FA paper mentioned above (Xia, 2007). In that case they found 
that the lack of functioning PALB2 led to issues with proper BRCA2 and RAD51 
functioning (Xia, 2007). Because BRCA2 and RAD51 are also breast cancer 
susceptibility genes, and the patient is a compound heterozygote for deleterious 
PALB2 variants, they predicted that this was the cause of the patient’s FA (Xia, 
2007). 
NCG_00139 is heterozygous for the truncating PALB2 variant, so it is 
possible that normal PALB2 protein is reduced enough that it has conferred an 
increased risk of breast cancer in this patient and her family. Alternatively, the 
two-hit hypothesis may apply, and she may have acquired a somatic mutation 
that destroys the remaining, functioning allele. The patient has a strong family 
history of breast cancer. Her sister was diagnosed with breast cancer at age 34 
and her mother was diagnosed at age 59. There is also a history of breast cancer 
on her paternal side, with an aunt diagnosed at age 48 and a great aunt 
diagnosed at an unknown age. This family history combined with a clearly 
pathogenic variant in a definitive breast cancer gene is a classic positive result 
for a family with hereditary breast cancer.  
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 SUM TOTAL 20 Assertion: Definitive  
A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) PALB2 
variants in NCGENES cancer patients. Black denotes a likely pathogenic variant, dark 
gray denotes a VUS, and light gray denotes a likely benign variant (The UniProt 
Consortium, 2015). Note the Leu939Trp variant was found in two patients. B. Clinical 
validity matrix for PALB2 used to make the assertion of “definitive” for this gene. C. PALB2 
variant count table showing number of variants per patient using different filters on 
NCGENES cancer cases and controls. 
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RAD51C   
RAD51 Paralog C (RAD51C) was cloned in 1998 and was recognized as 
a new member of the RAD51 family (Dosanjh, 1998). RAD51 and it’s paralogs 
encode proteins involved in recombination repair during meiosis and after DNA 
damage, which makes them candidates for cancer susceptibility genes (Masson, 
2001). It was discovered that cells with deficient RAD51C had reduced levels of 
Holliday junction resolvase activity and branch migration and revolution activity, 
suggesting that it plays a role in the resolving of Holliday junctions (Liu, 2004). 
Because several other breast cancer genes are also involved in resolving 
Holliday junctions, researchers hypothesized that RAD51C could function in a 
similar way.  
A hamster cell line with deficient RAD51C has been the basis for many of 
the functional studies of this gene. These cells have impaired DNA damage 
response and reduced levels of homologous recombination which together result 
in chromosomal instability (French, 2002; French, 2003). The cells’ DNA damage 
response and homologous recombination abilities were restored when 
transfected with normal human RAD51C. Following these studies an in vitro 
knockout experiment showed that gene conversion after a double-strand break is 
defective in cells deficient of RAD51C, reinforcing the speculation about the 
protein’s role in homologous recombination (Nagaraju, 2006). 
Immunofluorescence studies showed that RAD51C is essential for RAD51 
locus formation, and RAD51C localizes itself into foci at sites of DNA double 
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stranded breaks (Rodrigue, 2006). Inhibition of RAD51C lead to a decrease in 
cellular proliferation, which is indicative of failure to repair normal double 
stranded breaks during cell replication (Rodrigue, 2006). It has also been 
suggested that RAD51C is involved with G2/M checkpoint control, because 
depletion lead to phosphorylation and therefore inactivation of CHEK2 (Badie, 
2009). This information, taken together, solidified the suspicion that RAD51C 
may be linked to familial breast cancer. 
 Several studies found a convincing association between RAD51C 
mutations and breast and ovarian cancer families, but it appears that this 
association does not apply to families with breast cancer only (Loveday, 2012; 
Meindl, 2010; Pelttari, 2011). Clinical reports of RAD51C variants began in 2004, 
though the first report containing a clearly pathogenic variant in a breast cancer 
only family was not until 2011 (Vuorela, 2011). While the study did not find any 
common SNPs associated with breast cancer, they did identify a frameshifting 
deletion in one patient out of their Finnish cohort of 112 familial breast cancer 
patients that was not found in any of their 852 controls (Vuorela, 2011). Although 
segregation analysis could not be performed, this variant is likely pathogenic as it 
is truncating early on in the protein (Vuorela, 2011).  
Although there is a report of a probably pathogenic variant, there is 
considerably more evidence to suggest that RAD51C is not a breast cancer 
susceptibility gene. In the 2004 study the authors reported “no difference” in 
variants in 375 breast cancer cases compared to 388 healthy controls 
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(Rodríguez-López, 2004). Another attempt at a case-control study found 6 
pathogenic mutations in RAD51C. However, the pathogenic mutations were 
found exclusively in 6 probands from 6 hereditary breast and ovarian cancer 
families (Meindl, 2010). Five missense variants were identified in breast cancer 
only families, however, none of these were convincingly pathogenic and most 
were present in an equal or greater percentage of controls (Meindl, 2010).  
Similarly, Wong et al and Lu et al found missense variants in case series 
studies, but all were likely benign according to in silico prediction tools (Lu, 2012; 
Wong, 2011). Several other studies similarly provided no evidence for a 
RAD51C-familial breast cancer gene-disease association (Akbari, 2010; Osorio, 
2012; Romero, 2011; Thompson, 2012).  
Very recently Couch et al looked at mutations in 17 breast cancer 
predisposition genes, including RAD51C, in patients with triple negative breast 
cancer (Couch, 2015). Out of 1,824 patients they found 2 truncating variants in 6 
probands (Couch, 2015). Notably, these patients were unselected for a family 
history of breast cancer (Couch, 2015). This is the second study identifying 
truncating RAD51C variants in breast cancer patients, although no follow up 
studies were done to evaluate the variants’ pathogenicity (Couch, 2015). 
Though there were two reports of pathogenic variants in breast cancer 
patients in the literature, the considerable refuting evidence determined that 
RAD51C has a “disputed” causal association with familial breast cancer (Figure 
8C).  
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 The distribution of variants in NCGENES cancer patients can be seen in 
Figure 8A. NCG_00609 did have the variant Ile158Phe that was interpreted as a 
VUS. The individual is an ovarian cancer patient, who previously tested negative 
for BRCA1 and BRCA2 mutations. The in silico prediction tools predict this 
variant to be possibly or probably damaging, although it is not in a conserved 
domain. In fact, it is in the alternatively spliced exon 3, so it is likely not an 
important region of the gene (NCBI, Bethesda, MD). This weakly supports the 
hypothesis that RAD51C mutations may be pathogenic in ovarian cancer 
families. Overall, it is clear that in our NCGENES patient cohort the cancer 
patients do not have a greater burden of variants in RAD51C (Figure 8B). There 
are actually more variants per person in RAD51C in the controls than in the 
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 SUM TOTAL 13 Assertion: Disputed  
A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) RAD51C 
variants in NCGENES cancer patients. Dark gray denotes a VUS and light gray denotes a 
likely benign variant (The UniProt Consortium, 2015). Note that two of the variants were 
found in two patients each. B. Clinical validity matrix for RAD51C used to make the 
assertion of “evidence against” for this gene. C. RAD51C variant count table using 
different filters on NCGENES cancer cases and controls. This shows how many variants 
per person there were in each cohort. 
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RAD51D   
RAD51 Paralog D (RAD51D) was cloned in 1998 by Cartwright et al and 
1999 by Kawabata et al (Cartwright, 1998; Kawabata, 1999). Both predicted a 
328 amino acid protein with around an 83% sequence identity to the mouse 
protein (Cartwright, 1998; Kawabata, 1999). Several alternative transcripts were 
identified, and each transcript was expressed in all tissues (Kawabata, 1999).  
Takata et al studied the RAD51 paralogs and found that they all, including 
RAD51D, are involved in homologous recombination mediated gene targeting 
and in sister chromatid exchange (Takata, 2001). They also found RAD51D 
deficient human cells to be sensitive to the DNA cross-linking agent cisplatin, 
suggesting that it plays a role in DNA repair (Takata, 2001). In addition, Takata et 
al showed that RAD51D plays a role in RAD51 focus formation in response to 
DNA damage (Takata, 2001). Because BRCA2 is associated with RAD51 and 
RAD51D is essential for proper RAD51 function, malfunctioning RAD51D could 
affect the other proteins as well, which raised suspicions for RAD51D being 
candidate gene for cancer susceptibility (Chen, 1998). Loss of RAD51D is 
associated with embryonic lethality in mice, indicating that it is essential for cell 
survival (Pittman, 2000). This also shows that the loss of functioning RAD51D 
could be a mechanism for disease.  
Another group showed that RAD51D interacts with the BLM protein, which 
is known to act on Holliday Junctions with RAD51C (Braybrooke, 2003). They 
created a synthetic model of a Holliday junction and showed that the RAD51D-
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XRCC2 complex stimulated BLM to disrupt the Holliday junction (Braybrooke, 
2003). BLM is a tumor suppressor in humans, so by disrupting BLM’s normal 
activity RAD51D could play a role in cancer susceptibility (Braybrooke, 2003).  
Tarsounas et al reported that RAD51D is also involved in the maintenance 
of telomeres (Tarsounas, 2004). In the absence of normally functioning 
telomeres, chromosomes are left susceptible to enormous amounts of damage 
(Blackburn, 2001). By siRNA knockdown of about 50% of RAD51D, Tarsounas et 
al were able to show that human cells experienced telomere shortening and 
chromosome fusion as well as a 10-fold loss of cell viability by day 5 due to a 
lack of RAD51D (Tarsounas, 2004). Telomere shortening was also seen in 
mouse embryonic fibroblasts lacking RAD51D, further solidifying this role for 
RAD51D (Tarsounas, 2004). Though the telomerase enzyme is the main 
mechanism responsible for maintaining telomeres, it has also been hypothesized 
that homologous recombination can provide an alternative telomere lengthening 
mechanism, so it may make sense that deficient RAD51D would be affect 
telomere stability (Tarsounas, 2004).  
Rodríguez-López et al reported the first case-control study with a breast 
cancer cohort in 2004 (Rodríguez-López, 2004). They found a novel RAD51D 
missense variant (E233G) which they predict to be a low-penetrance breast 
cancer susceptibility allele (Rodríguez-López, 2004). The in silico structural 
prediction suggested that this variant could alter the function of the protein, so 
they determined that it could be potentially pathogenic (Rodríguez-López, 2004). 
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However, they performed segregation analysis for two families, and the variant 
did not completely segregate with disease (Rodríguez-López, 2004). They also 
noted that there was only an overrepresentation of this variant in site-specific 
breast cancer patients and not in all familial breast cancer patients (Rodríguez-
López, 2004).  
Further evidence against the E233G variant’s pathogenicity has since 
emerged out of another case-control study done by Dowty et al in 2008 (Dowty, 
2008). This group performed large-scale genotyping of the variant in over 1,500 
breast cancer patients and 600 controls and found no evidence for an 
association of E233G with breast cancer (Dowty, 2008). The group also 
performed segregation analysis of variants for families of probands regardless if 
they had a family history of breast cancer (Dowty, 2008). It was determined that 
the hazard ratio was not significantly higher in families with a history of breast 
cancer versus families with no reported family history (1.30 and 1.28, 
respectively) (Dowty, 2008). The authors concluded that their study was large 
enough to detect a moderate risk of breast cancer, but that a larger study would 
be required to determine if the variant conferred a very slight risk (Dowty, 2008). 
An additional group studied the E233G variant in 2010 and found that it 
was associated with breast cancer risk, but only when an XRCC3-T241M variant 
was also present (Jara, 2010). The group hypothesizes that variation in RAD51D 
may play a role in breast cancer susceptibility, but that it may be dependent on 
variation in other homologous recombination repair genes (Jara, 2010).  
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Though there is little evidence for a role of RAD51D in familial breast 
cancer, there is strong evidence that is plays a role in familial ovarian cancer 
susceptibility (Gutiérrez-Enríquez, 2014; Loveday, 2011; Osher, 2012; Pelttari, 
2012; Thompson, 2013; Wickramanayake, 2012). The risk is so significant in 
ovarian cancer families that it is recommended that families with a history of 
breast and ovarian cancer get tested for RAD51D variants regardless of how 
many ovarian cancer cases there are in the family (Gutiérrez-Enríquez, 2014). 
Therefore, the clinical validity of RAD51D with respect to familial ovarian cancer 
is very different from the clinical validity of the gene with respect to familial breast 
cancer. 
Because there are only a few probands with reported likely pathogenic 
variants in RAD51D and quite a bit of evidence against a role in breast cancer 
susceptibility, this gene has a clinical validity assertion of “disputed” with respect 
to its role in monogenic hereditary cancer susceptibility (Figure 9C). There are 
several functional assays that suggest that RAD51D could be a good candidate 
gene for breast cancer, so larger studies are needed to determine if rare 
RAD51D truncating variants truly play a role in caner susceptibility. 
 Upon analyzing RAD51D variants, there was one missense VUS found in 
NCG_00730 (Figure 9A). This variant is very rare and falls in the nucleotide 
binding domain of RAD51D, which is a conserved domain, although in silico 
predictions expect the variant to be benign (NCBI, Bethesda, MD). This patient 
was diagnosed with a meningioma at age 54. She did not have breast cancer nor 
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did she report any family history of breast cancer. However, the patient was 
adopted and there was no biological family history available.   
 Figure 9B shows that while the two NCGENES cohorts have a similar 
overall number of RAD51D variants per person, the cancer cohort has more rare 
variants per person than the controls (0.045 and 0.014, respectively). This does 
provide some evidence that cancer patients may harbor more potentially 
damaging variants in this gene, which could indicate that it plays some role in 
disease. This is weak evidence, however, it is worth noting and potentially 
following up the investigation of some of the missense variants with functional 
studies. It is possible that truncating RAD51D variants are extremely rare, and 
the NCGENES cancer cohort, being only 102 patients, is not large enough to find 
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A. Lolliplot showing the distribution of rare (<1% ExAC population frequency) RAD51D 
variants in NCGENES cancer patients. Dark gray denotes a VUS and light gray denotes a 
likely benign variant (Gruver, 2005). Note the Asp90Gly variant was found in two patients. 
B. Clinical validity matrix for RAD51D used to make the assertion of “disputed” for this 
gene. C. RAD51D variant count table using different filters on NCGENES cancer cases 





 The literature review process is extremely important for determining the 
clinical validity of a gene-disease association. The literature search process was 
different for every gene. It often started by searching for the gene in OMIM to 
determine when the gene was discovered and when the first clinical report 
implicating the gene in hereditary breast cancer was published (Online 
Mendelian Inheritance in Man, 2015). Beyond the OMIM search PubMed was 
also searched using different combinations of search terms to be sure that no 
publications were missed that could impact the clinical validity (PubMed Health, 
Bethesda, MD). Often a separate literature search would need to be done for 
clinical case reports and functional data. It is important to determine which gene-
level functional data is relevant to the phenotype being studied. The ClinGen 
group is still working to try to develop a more streamlined literature search 
process so that gene curators will not miss any important information that they 
could use to make an assertion about a gene. 
 The assertion matrix has proved to be a very useful tool to summarize 
gene curation data and to help make an unbiased assertion. Biased assertions 
may happen if the curator looks at several different genes for the same 
phenotype and unconsciously begins to assign a clinical validity to them relative 
to each other, rather than objectively. The assertion matrix has a fixed point 
system and each gene gets a quantitative score, which eliminates some of the 
curator’s bias. However, the quantitative score has several issues that are still up 
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for debate, such as if certain aspects of the data should be weighted differently 
than others. At this point the assertion matrix development is ongoing, and it is 
not meant to be used as a decisive assertion about a gene. If curators and 
experts discuss a gene and feel that the assertion matrix did not accurately 
represent the data available for the gene they may assign a different clinical 
validity. 
 When looking at variants in a particular gene in cancer cases and controls 
they must be prioritized. Variants were filtered based on allele frequency in ExAC 
and the type of variant, excluding variants with a frequency greater than 1% and 
synonymous and intronic variants (Exome Aggregation Consortium, Cambridge, 
MA). The remaining variants were prioritized based on the variant effect and the 
CADD PHRED score (Kircher, 2014). While most of the variants were interpreted 
as likely benign or variants of unknown significance, there was one likely 
pathogenic variant found in PALB2. The fact that PALB2 is a definitive breast 
cancer susceptibility gene contributed to the confidence in interpreting that 
variant likely pathogenic. 
 Comparing the number of variants per person in a particular gene in cases 
versus controls could suggest whether cancer cases have a higher burden of 
mutations in that gene than the controls, though a true case-control cohort with a 
statistical analysis would need to be done to determine if this is true. For all six 
genes, when considering all of the called variants in the gene, there was no 
major difference between the number of variants in cases and controls. When 
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filtering for all rare variants in PALB2, RAD51D, and RINT1 all seem to have a 
greater burden in cancer cases versus controls, although a statistical analysis 
was not done. When considering PALB2, the only gene in this group found to be 
a definitive breast cancer susceptibility gene, it is the only gene to show a greater 
burden of rare truncating variants in cancer cases versus controls. Notably, the 
rest of the genes either had no truncating variants in cases or controls or one 
truncating variant in a control subject. The lack of truncating variants identified 
could be due to the relatively small sample size, as I suspect is the case for 
SLX4 because there do seem to be more rare missense variants in cases than 
controls. The lack of truncating variants could also be due to weak evidence that 
the gene is not actually associated with disease, as I suspect is the case with 
RAD51C because there are actually slightly more rare variants in controls versus 
cancer cases. However, this would be more convincing if there was an excess of 
truncating variants in controls. It is possible that truncating variants are so rare 
that this study was not large enough to detect appreciable differences.  
 There were a total of 403 patients enrolled in the NCGENES study at the 
time of my analysis. When patients are enrolled they are put in phenotypic 
groups. Cancer is the largest group in the study, but gets the fewest positive 
results from whole exome sequencing; in other words, individuals with suspected 
hereditary cancer susceptibility have a low diagnostic yield of germline variants 
that could provide a plausible molecular diagnosis. This could be due to several 
reasons. One possibility is that a substantial percentage of hereditary cancer is 
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due to unknown genes and unknown mechanisms. This is the reason that doing 
research sweeps is so important. For patients that get a negative result, a 
research sweep could potentially identify a pathogenic variant in a novel disease 
gene. Because such a large percentage of hereditary cancer cases get a 
negative result when evaluated on the cancer diagnostic list, it is useful to have 
the data for the whole exome rather than just a gene panel so that other possible 
mutations can be evaluated. This is particularly true in a research setting, 
although it is less certain whether information about novel genes will provide 
clinically important information, so it remains to be determined whether exome 
sequencing should be considered as a routine clinical diagnostic test in patients 
with suspected hereditary cancer susceptibility. 
Another potential explanation for the low diagnostic yield is that most 
cancer cases are explained by multifactorial causation and chance somatic 
mutations. Many genetic variants have very low penetrance, so development of 
disease could be dependent on environmental factors or other low penetrance 
alleles combined. This explanation may be particularly valid in patients with early-
onset cancer but no particular family history suggestive of inherited 
predisposition, or in patients in whom the pedigree analysis suggests a relatively 
modest chance of inherited predisposition. For example, a family with two or 
three cancer cases might possibly signify a hereditary predisposition but may be 
equally likely to be multifactorial in nature. In these cases, absence of a 
compelling mutation in a known cancer predisposition gene could support the 
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conclusion that the individual’s cancer was multifactorial and not cause by a 
single highly penetrant gene mutation. 
 I have presented a strategy for gene evaluation that will benefit clinicians 
and researchers when they are attempting to decipher sequencing data. It will 
help physicians to better explain sequencing results to their patients and 
hopefully give more patients a clearer picture of their genetic susceptibility to 
cancer. Through careful review of the literature and input from experts in different 
fields this method is being implemented in many fields of medicine, and this will 
hopefully lead to a better understanding of all genetic diseases.   
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